Issue 3 2022

European Pharmaceutical Review Issue 3 2022

In this issue experts explore the development of targeted protein degradation drugs, how potential legislative changes may impact the EU and selecting the right downstream process for bi-specific antibodies. Also featured in this journal, how RMM can enable efficient shutdown recovery, five critical areas for data integrity in life sciences and so much more!

Included in this issue:

  • EVENT REVIEW
    European Pharmaceutical Review’s The Future of Bio/Pharmaceutical Analysis Online Summit
  • QA/QC Microbiology/RMM
    Testing non-inferiority for accuracy of quantitative microbiological methods
    Edwin van den Heuvel and Maliheh Heidari, Eindhoven University of Technology, Kathrin Möllenhoff, Heinrich-Heine-University, and Pieta IJzerman-Boon, Center for Mathematical Sciences
  • MANUFACTURING
    The importance of sterility testing in biopharmaceutical manufacturing
    Thermo Fisher Scientific
  • VACCINE DEVELOPMENT
    Anatomy of a ‘correlate of protection’ for T-cell vaccines
    Thomas Rademacher, Emergex Vaccines
  • HPAPI
    The challenge of handling highly potent API and ADCs in analytical chemistry
    Elodie Barrau and Olivia Jones, Eurofins
  • GUIDE TO: Data Integrity
    Reducing human error with better technology
    Charles River
  • Drug Development
    Global Blood Therapeutics: driving innovation in sickle cell disease
    Sebastian Stachowiak, Global Blood Therapeutics (GBT)